Program
efserakefusp alfa
Also written as “SHR-1501”, “SHR-1501+BCG” and “SHR-1501 for Injection”.
In Jiangsu HengRui Medicine's pipeline, IL-15
. Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Feb 13, 20266 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 64 open or running | phase 3since Feb 13, 2026 | May 9, 2019 | Dec 2027phase 2 · NCT07073534 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1501
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2019First study: phase 1 study in Advanced MalignanciesFirst studyNCT03995472 · 14 enrolled · Australia, China
- Jul 14, 2019Phase 1 study in Advanced MalignanciesNCT04025957 · 19 enrolled · China
- May 19, 2022Phase 2 study in High-risk NMIBCNCT05410730 · 150 planned · China
- Jul 9, 2025Phase 2 study in NeoplasmsNCT07073534 · 203 planned · China
- Feb 13, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsPhase 3 reachedNCT07424287 · 236 planned · China
- Jul 21, 2026Phase 3 study in Papillary-Only Non-muscle-invasive Bladder CancerNCT07726992 · 750 planned · China
Ahead
- Dec 2027Primary completion: phase 2 study in NeoplasmsNCT07073534
- Dec 2029Primary completion: phase 3 study in Papillary-Only Non-muscle-invasive Bladder CancerNCT07726992
- Jun 2030Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT07424287
TargetBeta
“IL-15”the company's pipeline, read by Claude · source
“A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activity. Upon administration, efserakefusp alfa activates and increases the levels of natural killer (N…”NCIt, read by Claude
“A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), ”NCIt, by rule
Other programs on IL15
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nogapendekin alfa inbakiceptrule | ImmunityBio | phase 3 | 45 |
| belacabnagene franleucelrule | nkarta-inc | phase 2 | 3 |
| GIA632 | Novartis | phase 2 | 3 |
| SPGL008rule | 3SBio | phase 2 | 3 |
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07726992Papillary-Only Non-muscle-invasive Bladder Cancer · China | 3 | Recruiting | Dec 2029 | 750 |
| NCT07424287Non-Muscle Invasive Bladder Neoplasms · China | 3 | Recruiting | Jun 2030 | 236 |
| NCT07073534Neoplasms · China | 2 | Recruiting | Dec 2027 | 203 |
| NCT05410730High-risk NMIBC · China | 2 | Recruiting | May 2025 | 150 |
| NCT04025957Advanced Malignancies · China | 1 | Completed | Jul 31, 2022 | 19 |
| NCT03995472Advanced Malignancies · Australia, China | 1 | Completed | Jan 12, 2023 | 14 |
How it is read
Names in the registry
- “SHR-1501”, 3 entries
- “SHR-1501+BCG”, 1 entry
- “SHR-1501 for Injection”, 1 entry
- “SHR-1501, Adebrelimab”, 1 entry
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 3 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.